2025년
한국질량분석학회 여름학술대회 및 총회
2025. 08.27 (수) ~ 2025. 08.29 (금)
부산항국제전시컨벤션센터(BPEX)
초록검색
| 제목 | IP-MS Based Quantification of AFP and AFP-Fuc% for Early Detection of Hepatocellular Carcinoma |
|---|---|
| 작성자 | 서한슬 ((재)씨젠의료재단) |
| 발표구분 | 포스터발표 |
| 발표분야 | 4. Medical / Pharmaceutical Science |
| 발표자 |
서한슬 ((재)씨젠의료재단) |
| 주저자 | 서한슬 ((재)씨젠의료재단) |
| 교신저자 |
백제현 ((재)씨젠의료재단) |
| 저자 |
서한슬 ((재)씨젠의료재단) 박주리 ((재)씨젠의료재단) 김효진 ((재)씨젠의료재단) 이세영 ((재)씨젠의료재단) 양원석 ((재)씨젠의료재단) 백제현 ((재)씨젠의료재단) |
|
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Early detection is critical for improving survival; however, conventional diagnostic assays for biomarkers such as alpha-fetoprotein (AFP), AFP-L3, and PIVKA-II have limited sensitivity and specificity, hindering effective early diagnosis. To overcome these limitations, we developed a clinically applicable, high-accuracy diagnostic assay using immunoprecipitation combined with multiple reaction monitoring (IP-MRM). The assay quantifies serum AFP level and fucosylated AFP portion, after enriching via the KingFisher™ automated system. This assay was developed and validated according to Clinical and Laboratory Standards Institute (CLSI) guidelines to ensure real-world applicability. Analytical evaluation showed excellent linearity (R² ≥ 0.99), imprecision within ±15%, and accuracy within ±20%. Clinical assessment demonstrated improved sensitivity and diagnostic accuracy compared to conventional AFP-L3%. Our IP-MRM assay meets CLSI standards and offers clear clinical advantages, supporting its potential as a robust tool for early HCC detection in clinical settings. By addressing existing assay limitations, this platform may enhance early diagnosis and improve patient outcomes in hepatocellular carcinoma. |
|